Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Prostate Cancer | Research

A novel tumor purity and immune infiltration-related model for predicting distant metastasis-free survival in prostate cancer

Authors: Qiang Su, Yongbei Zhu, Bingxi He, Bin Dai, Wei Mu, Jie Tian

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

umor cells, immune cells and stromal cells jointly modify tumor development and progression. We aim to explore the potential effects of tumor purity on the immune microenvironment, genetic landscape and prognosis in prostate cancer (PCa).

Methods

Tumor purity of prostate cancer patients was extracted from The cancer genome atlas (TCGA). Immune cellular proportions were calculated by the CIBERSORT. To identify critical modules related to tumor purity, we used weighted gene co-expression network analysis (WGCNA). Using STRING and Cytoscape, protein–protein interaction (PPI) networks were constructed and analyzed. A Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, Disease Ontology (DO), and Gene Set Enrichment Analysis (GSEA) enrichment analysis of identified modules was conducted. To identify the expression of key genes at protein levels, we used the Human Protein Atlas (HPA) platform.

Results

A model of tumor purity score (TPS) was constructed in the gene expression omnibus series (GSE) 116,918 cohort. TCGA cohort served as a validation set and was employed to validate the TPS. TPS model, as an independent prognostic factor of distant metastasis‐free survival (DMFS) in PCa. Patients had higher tumor purity and better prognosis in the low-TPS group. Tumor purity was related to the infiltration of mast cells and macrophage cells positively, whereas related to the infiltration of dendritic cells, T cells and B cells negatively in PCa. The nomogram based on TPS, Age, Gleason score and T stage had a good predictive value and could evaluate the prognosis of PCa metastasis. GO and KEGG enrichment analyses showed that hub genes mainly participate in T cell activation and T-helper lymphocytes (TH) differentiation. Hub genes were mainly enriched in primary immunodeficiency disease, according to DO analysis. SLAMF8 was identified as the most critical gene by Cytoscape and HPA analysis.

Conclusions

Dynamic changes in the immune microenvironment associated with tumor purity could correlate with a poor DMFS of low-purity PCa. The TPS can predict the DMFS of PCa. In addition, prostate cancer metastases may be related to immunosuppression caused by a disorder of the immune microenvironment.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
Cao W, Chen H, Yu Y, Li N, Chen W. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783–91.CrossRefPubMedPubMedCentral
3.
Taitt H. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. Am J Mens Health. 2018;12(6):1807–23.CrossRefPubMedPubMedCentral
4.
Aran D, Sirota M, Butte A. Systematic pan-cancer analysis of tumour purity. Nat Commun. 2015;6:8971.CrossRefPubMed
5.
6.
Mao Y, Feng Q, Zheng P, Yang L, Liu T, Xu Y, Zhu D, Chang W, Ji M, Ren L, et al. Low tumor purity is associated with poor prognosis, heavy mutation burden, and intense immune phenotype in colon cancer. Cancer Manag Res. 2018;10:3569–77.CrossRefPubMedPubMedCentral
7.
Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird P, Levine D, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.CrossRefPubMed
8.
9.
Edgar R, Domrachev M, Lash A. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–10.CrossRefPubMedPubMedCentral
10.
Jain S, Lyons C, Walker S, McQuaid S, Hynes S, Mitchell D, Pang B, Logan G, McCavigan A, O’Rourke D, et al. Validation of a metastatic assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. Ann Oncol. 2018;29(1):215–22.CrossRefPubMed
11.
Wang Z, Jensen M, Zenklusen J. A practical guide to The Cancer Genome Atlas (TCGA). Methods Mol Biol (Clifton, NJ). 2016;1418:111–41.CrossRef
12.
13.
Newman A, Liu C, Green M, Gentles A, Feng W, Xu Y, Hoang C, Diehn M, Alizadeh A. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.CrossRefPubMedPubMedCentral
14.
Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W, Smyth G. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7): e47.CrossRefPubMedPubMedCentral
15.
16.
Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for cox’s proportional hazards model via coordinate descent. J Stat Softw. 2011;39(5):1–13.CrossRefPubMedPubMedCentral
17.
Heagerty P, Lumley T, Pepe M. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–44.CrossRefPubMed
18.
Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou K, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43:D447–52.CrossRefPubMed
19.
Shannon P, Markiel A, Ozier O, Baliga N, Wang J, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.CrossRefPubMedPubMedCentral
20.
21.
Yu G, Wang L, Yan G, He Q. DOSE: an R/Bioconductor package for disease ontology semantic and enrichment analysis. Bioinformatics (Oxford, England). 2015;31(4):608–9.PubMed
22.
Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2(3):100141.PubMedPubMedCentral
23.
Zhang C, Cheng W, Ren X, Wang Z, Liu X, Li G, Han S, Jiang T, Wu A. Tumor purity as an underlying key factor in glioma. Clin Cancer Res. 2017;23(20):6279–91.CrossRefPubMed
24.
Shao L, Yan Y, Liu Z, Ye X, Xia H, Zhu X, Zhang Y, Zhang Z, Chen H, He W, et al. Radiologist-like artificial intelligence for grade group prediction of radical prostatectomy for reducing upgrading and downgrading from biopsy. Theranostics. 2020;10(22):10200–12.CrossRefPubMedPubMedCentral
25.
Su Q, Liu Z, Chen C, Gao H, Zhu Y, Wang L, Pan M, Liu J, Yang X, Tian J. Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy. Cancer Med. 2021;10(18):6492–502.CrossRefPubMedPubMedCentral
26.
Su Q, Dai B, Zhang S. Construction of miRNA-mRNA network and a nomogram model of prognostic analysis for prostate cancer. Transl Cancer Res. 2022;11(8):2562–71.CrossRefPubMedPubMedCentral
27.
Su Q, Dai B, Zhang H, Zhang S. Discovering gene signature shared by prostate cancer and neurodegenerative diseases based on the bioinformatics approach. Comput Math Methods Med. 2022;2022:8430485.CrossRefPubMedPubMedCentral
28.
Shao L, Liu Z, Yan Y, Liu J, Ye X, Xia H, Zhu X, Zhang Y, Zhang Z, Chen H, et al. Patient-level prediction of multi-classification task at prostate MRI based on end-to-end framework learning from diagnostic logic of radiologists. IEEE Trans Biomed Eng. 2021;68(12):3690–700.CrossRefPubMed
29.
Woo J, Liss M, Muldong M, Palazzi K, Strasner A, Ammirante M, Varki N, Shabaik A, Howell S, Kane C, et al. Tumor infiltrating B-cells are increased in prostate cancer tissue. J Transl Med. 2014;12:30.CrossRefPubMedPubMedCentral
30.
Ihle C, Provera M, Straign D, Smith E, Edgerton S, Van Bokhoven A, Lucia M, Owens P. Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients. J Immunother Cancer. 2019;7(1):293.CrossRefPubMedPubMedCentral
31.
Huen N, Pang A, Tucker J, Lee T, Vergati M, Jochems C, Intrivici C, Cereda V, Chan W, Rennert O, et al. Up-regulation of proliferative and migratory genes in regulatory T cells from patients with metastatic castration-resistant prostate cancer. Int J Cancer. 2013;133(2):373–82.CrossRefPubMedPubMedCentral
32.
Hayashi T, Fujita K, Matsushita M, Nonomura N. Main inflammatory cells and potentials of anti-inflammatory agents in prostate cancer. Cancers. 2019;11(8):1153.CrossRefPubMedPubMedCentral
33.
Zhao S, Lehrer J, Chang S, Das R, Erho N, Liu Y, Sjöström M, Den R, Freedland S, Klein E, et al. The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target. J Natl Cancer Inst. 2019;111(3):301–10.CrossRefPubMed
34.
Hirsch H, Iliopoulos D, Joshi A, Zhang Y, Jaeger S, Bulyk M, Tsichlis P, Shirley Liu X, Struhl K. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell. 2010;17(4):348–61.CrossRefPubMedPubMedCentral
35.
Zhao X, Hu D, Li J, Zhao G, Tang W, Cheng H. Database mining of genes of prognostic value for the prostate adenocarcinoma microenvironment using the cancer gene atlas. Biomed Res Int. 2020;2020:5019793.PubMedPubMedCentral
36.
Hwang J, Joung J, Shin S, Choi M, Kim J, Kim Y, Park W, Lee S, Lee K. Ad5/35E1aPSESE4: a novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements. Cancer Lett. 2016;372(1):57–64.CrossRefPubMed
37.
Lee J, Green M, Huppert L, Chow C, Pierce R, Daud A. The liver-immunity nexus and cancer immunotherapy. Clinical cancer Res. 2022;28(1):5–12.CrossRef
38.
Li Z, Zhao S, Zhu S, Fan Y. MicroRNA-153-5p promotes the proliferation and metastasis of renal cell carcinoma via direct targeting of AGO1. Cell Death Dis. 2021;12(1):33.CrossRefPubMedPubMedCentral
39.
Lee W, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao M, Hubert S, Tang C, Wu C, et al. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol. 2020;21(1):271.CrossRefPubMedPubMedCentral
Metadata
Title
A novel tumor purity and immune infiltration-related model for predicting distant metastasis-free survival in prostate cancer
Authors
Qiang Su
Yongbei Zhu
Bingxi He
Bin Dai
Wei Mu
Jie Tian
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01522-8

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Research

A systematic review and meta-analysis of the effects of non-pharmacological interventions on quality of life in adults with multiple sclerosis

Research

Comprehensive analysis of research related to rehabilitation and COVID-19, hotspots, mapping, thematic evolution, trending topics, and future directions

Review

Competitive endogenous network of circRNA, lncRNA, and miRNA in osteosarcoma chemoresistance

Review

Review of surgical treatment of iatrogenic iliofemoral artery injury in the pediatric population after catheterization

Review

Incidence and risk factors for pressure injuries in patients who have undergone vascular operations: a scoping review

Review

Dysregulated cholesterol regulatory genes in hepatocellular carcinoma